Association between extended-spectrum β-lactamase-producing Escherichia coli and oral third-generation cephalosporins

Infect Control Hosp Epidemiol. 2022 Feb;43(2):261-263. doi: 10.1017/ice.2020.1400. Epub 2021 Jan 18.

Authors

Hiroki Hosokawa¹, Satoru Mitsuboshi², Hirokazu Isobe³, Kenichi Kobayashi⁴, Hiroshi Moro⁵, Toshiaki Kikuchi⁵

Affiliations

¹ Department of Pharmacy, Agano City Hospital, Niigata, Japan.
² Department of Pharmacy, Kaetsu Hospital, Niigata, Japan.
³ Department of Pharmacy, Niigata University Medical and Dental Hospital, Niigata, Japan.
⁴ Department of Pharmacy, Nagaoka Red Cross Hospital, Niigata, Japan.
⁵ Department of Respiratory Medicine and Infectious Disease, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.

PMID: 33455590
DOI: 10.1017/ice.2020.1400

No abstract available

MeSH terms

Anti-Bacterial Agents / therapeutic use
Cephalosporins / pharmacology
Cephalosporins / therapeutic use
Escherichia coli Infections* / drug therapy
Escherichia coli*
Humans
Microbial Sensitivity Tests
beta-Lactamases

Substances

Anti-Bacterial Agents
Cephalosporins
beta-Lactamases